The Central Nervous System as a Sanctuary Site in ALK-Positive Non–Small-Cell Lung Cancer  by Gainor, Justin F. et al.
1570 Journal of Thoracic Oncology ®  •  Volume 8, Number 12, December 2013
Anaplastic lymphoma kinase (ALK) gene rearrangements define a 
distinct molecular subset of non–small-cell lung cancer that is highly 
responsive to treatment with the ALK inhibitor crizotinib. Recently, it 
has been recognized that the brain is a frequent site of relapse among 
ALK-positive patients treated with crizotinib. In this report, we 
expand on these observations and present a series of ALK-positive 
patients with two distinct forms of metastatic, central nervous system 
involvement: intramedullary spinal cord metastasis and leptomenin-
geal carcinomatosis.
Key Words: Anaplastic lymphoma kinase, ALK, Intramedullary spi-
nal cord metastasis, Leptomeningeal carcinomatosis.
(J Thorac Oncol. 2013;8: 1570–1573)
Anaplastic lymphoma kinase (ALK) gene rearrangements have emerged as important oncogenic drivers in non–
small-cell lung cancer (NSCLC). Identified in 3% to 5% of 
patients, ALK rearrangements are associated with distinct 
clinical and pathologic features, such as younger age, light 
or never smoking history, and adenocarcinoma histology.1 In 
addition, ALK rearrangements confer sensitivity to treatment 
with the multitargeted ALK tyrosine kinase inhibitor crizo-
tinib.2 In single-arm studies, crizotinib has been associated 
with an objective response rate of 60% and a median progres-
sion-free survival of 8 to 10 months.3 In a recently reported 
phase III trial (PROFILE 1007), ALK-positive patients treated 
with crizotinib in the second-line setting experienced statisti-
cally significant improvements in objective response rate and 
progression-free survival compared with those receiving stan-
dard, single-agent chemotherapy.4
In recent years, metastatic involvement of the central 
nervous system (CNS) has been recognized as an emerging 
complication in patients with ALK-positive NSCLC. In the 
PROFILE 1007 trial, for example, approximately 35% of 
ALK-positive patients had brain metastases at the time of 
study entry.4 In addition, several investigators have described 
the development of new or progressive brain metastases in 
patients receiving crizotinib.5–7 In this study, we expand on 
these reports and present a series of ALK-positive patients 
with two distinct forms of metastatic CNS involvement: intra-
medullary spinal cord metastasis (ISCM) and leptomeningeal 
carcinomatosis (LC).
Cases were identified through a clinical database of 
ALK-positive patients (n = 96) seen at the Massachusetts 
General Hospital between 2007 and 2013. All patients had 
advanced NSCLC. Medical records were reviewed to extract 
data on clinical features and treatment histories, including sites 
of disease. This study was performed through an Institutional 
Review Board–approved protocol.
CASE PRESENTATIONS
Case 1
Case 1 is a 31-year-old man with limited smoking his-
tory (10 pack-years) and stage IV NSCLC harboring an ALK 
rearrangement. He was treated with first-line cisplatin/peme-
trexed/bevacizumab but experienced disease progression 
after four cycles. In October 2010, he began treatment with 
crizotinib, achieving a partial response. Crizotinib was con-
tinued until July 2012 when note was made of an enlarging 
gastrohepatic lymph node. Because of ongoing clinical ben-
efit, crizotinib was continued beyond progression. In January 
2013, however, the patient experienced acute neck pain and 
paresthesias in the left upper extremity after weightlifting. 
Symptoms of bowel and bladder dysfunction were absent. 
Magnetic resonance imaging (MRI) of the cervical spine 
revealed a 4.2-cm, T2-hyperintense mass in the cervical spine 
(C3–5), consistent with an ISCM (Fig. 1). Additional imag-
ing also revealed a 3-mm intramedullary lesion in the thoracic 
spine (T12) and a 7-mm lesion within the putamen. A baseline 
MRI of the spine was unavailable; nevertheless, brain MRI 
at diagnosis showed no evidence of intracranial metastases. 
Neurosurgical interventions, including biopsy, were not rec-
ommended given the patient’s minimal baseline deficits and 
concerns for excess neurological morbidity related to any 
procedure. Crizotinib was discontinued and radiation therapy 
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directed at C1–7 was initiated, resulting in improved pain and 
neurological symptoms. In May 2013, a repeat MRI of the 
cervical spine demonstrated an interval decrease in size of the 
cervical intramedullary lesion (Fig. 2).
Case 2
Case 2 is a 37-year-old woman with a minimal smoking 
history (<1 pack-year) and stage IV NSCLC. Baseline tumor 
genotyping was negative for mutations in epidermal growth 
factor receptor (EGFR) and KRAS. She was treated with six 
cycles of first-line carboplatin/pemetrexed/bevacizumab, 
achi eving a near complete response. Thereafter, she received 
maintenance therapy with pemetrexed and bevacizumab. After 
6 months of maintenance therapy, she developed disease pro-
gression in the right iliac crest and left lower lobe of the lung. 
A repeat biopsy was subsequently performed to obtain addi-
tional tissue for molecular characterization. This revealed an 
ALK rearrangement. She therefore began treatment with crizo-
tinib and experienced a significant reduction in the size of her 
left lower lobe lung mass. A repeat computed tomography scan 
performed approximately 7 months after initiation of crizotinib 
demonstrated continued systemic disease control. Less than 1 
week later, however, the patient developed nausea, vomiting, 
and a severe frontal headache requiring hospital admission. 
Of note, a brain MRI obtained 1 week before showed no evi-
dence of brain metastases. The patient was examined by the 
neurology service, and a lumbar puncture was performed. 
Cytological evaluation of the cerebrospinal fluid (CSF) was 
positive for malignant cells, consistent with a diagnosis of 
LC. Despite initial symptomatic improvement after the lum-
bar puncture, she developed recurrent headaches, seizures, and 
worsening functional status. She was treated with analgesics 
and antiepileptics but was soon transitioned to supportive care. 
She died shortly thereafter.
DISCUSSION
Metastatic involvement of the CNS is a frequent com-
plication in patients with lung cancer.8 Indeed, up to 40% of 
patients with NSCLC develop brain metastases during the 
course of their disease.9 Less often, however, lung cancer may 
involve other sites along the craniospinal axis, such as the 
spinal cord parenchyma (i.e., ISCMs) and the leptomeninges 
(i.e., LC).
In NSCLC, ISCMs are identified in less than 2% of 
patients, and less than 150 cases have been described in the 
medical literature.10,11 ISCMs are thought to arise predomi-
nantly through arterial dissemination although venous spread 
and direct invasion from contiguous structures have also been 
proposed.10 Development of ISCMs has also been attributed to 
meningeal spread in patients with concurrent LC, which has 
been reported in approximately 20% of patients with ISCMs.12
To date, descriptions of ISCMs in NSCLC have gener-
ally lacked tumor-genotyping information.10 In this study, we 
report the first case of ISCM in a patient with ALK-positive 
NSCLC. After identification of this index patient, three addi-
tional cases of ISCMs were found among 96 ALK-positive 
patients (4 of 96 or 4.17%) through a retrospective chart 
review (patients 2–4; Table 1). All four patients had a history 
of brain metastases; nevertheless, none had evidence of LC. 
The time interval from NSCLC diagnosis to development of 
ISCMs exceeded 15 months in all patients, suggesting that 
longer survival may place patients at increased risk for devel-
opment of late complications, such as ISCMs. Notably, all 
FIGURE 1.  T2 Magnetic resonance imaging study demon-
strating a heterogeneous, lobular mass extending from C3 to 
C5 (arrow).
FIGURE 2.  T2 Magnetic resonance imaging study per-
formed after completion of radiation therapy, demonstrating 
an interval reduction in the size of the intramedullary spinal 
cord lesion (arrow).
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four patients in this series were treated with radiation therapy. 
Nevertheless, the optimal treatment approach for patients with 
ISCMs has not been well defined, because most reports are 
retrospective and limited in size.10–12 In general, management 
strategies have included radiation therapy, surgical resection, 
chemotherapy, or a combination of these modalities.11
Like ISCMs, LC is a rare complication of lung can-
cer, identified in approximately 5% of patients.13 Recently, 
the incidence of LC seems to have increased, likely because 
of improved neuroimaging techniques and new, more effec-
tive systemic therapies. LC is thought to arise predominantly 
through hematogenous spread or through direct extension of 
parenchymal lesions.14 To date, only isolated descriptions of 
LC in ALK-positive NSCLC have been reported.5,15,16
After identification of the index patient described in 
case 2, we found four additional cases of LC among 96 ALK-
positive patients (5 of 96 or 5.21%) through a retrospective 
chart review (patients 2–5; Table 2). All patients were symp-
tomatic at the time of LC diagnosis, with the most common 
symptom being headache. In most cases, the diagnosis of LC 
was made based on cytological analysis of the CSF, which 
confirmed the presence of malignant cells. Interestingly, like 
ALK-positive patients with ISCMs, the time interval from 
NSCLC diagnosis to development of LC was fairly long (≥9 
months in 4 of 5 cases), suggesting that LC may also be a late 
complication.
This series also raises important questions regarding 
the management of LC in ALK-positive patients. Currently, 
there is no defined standard of care for the treatment of LC 
in patients with NSCLC as a whole, and such patients have 
traditionally been excluded from clinical trial participation. 
Thus, the optimal approach for ALK-positive patients is also 
unclear.5,15,16 In general, treatment strategies have included 
intrathecal chemotherapy, systemic chemotherapy, surgery 
(e.g., ventriculoperitoneal shunts), or radiation therapy.13,14
It is noteworthy that a majority of patients in this series, 
both those with ISCMs and LC, had either previously received 
or were still being treated with crizotinib at the time they were 
diagnosed with these CNS complications (Tables 1 and 2). It 
has recently been shown that crizotinib administration pro-
duces low CSF to plasma ratios, suggestive of poor blood–
brain barrier penetration.5 Furthermore, the brain seems to be 
TABLE 1.  ALK-Positive Patients with Intramedullary Spinal Cord Metastases
Patient No. Age Sex Clinical Presentation Spinal Cord Level
Interval from 
Primary NSCLC 
Diagnosis to ISCM
Brain 
Metastases
Prior 
Crizotinib
Crizotinib 
Duration
ISCM 
Treatment
1 31 M Neck pain, left upper 
extremity paresthesias
Cervical, thoracic 33 Months Yes Yesa 30 Months RT
2 64 M Bilateral lower extremity 
weakness, urinary 
retention
Conus medullaris 60 Months Yes Yesa 21 Months RT
3 59 F Back pain, right lower 
extremity weakness
Thoracic 16 Months Yes No — RT
4 46 M Asymptomatic Cervical, thoracic, 
lumbar, and conus 
medullaris
103 Months Yes Yes 12 Months RT
aIndicates that intramedullary spinal cord metastases developed while the patient was receiving crizotinib.
ALK, anaplastic lymphoma kinase; ISCM, intramedullary spinal cord metastases; NSCLC, non–small-cell lung cancer; RT, radiation therapy.
TABLE 2.  ALK-Positive Patients with Leptomeningeal Carcinomatosis
Patient No. Age Sex
Clinical  
Presentation
CSF  
Cytology
Interval from 
1º NSCLC 
Diagnosis to 
LC
Brain 
Metastases
Prior 
Crizotinib
Crizotinib 
Duration
LC  
Treatment
1 37 F Headache, nausea, 
vomiting, seizures
+ 22 Months No Yesa 7 Months Supportive care
2 57 F Headache, lower 
extremity 
paresthesias, blurred 
vision
+ 21 Months Yes No N/A Whole-brain radiotherapy, 
temozolomide
3 45 M Slurred speech, gait 
instability
+ 13 Months Yes Yes 4 Months Whole-brain radiotherapy
4 39 F Headache, pressure 
behind eyes
ND 9 Months No Yesa 11 Months Whole-brain radiotherapy
5 62 F Headache + 1 Month Yes No N/A Resection, whole-brain 
radiotherapy
aIndicates that leptomeningeal carcinomatosis developed while the patient was receiving crizotinib.
ALK, anaplastic lymphoma kinase; CSF, cerebrospinal fluid; LC, leptomeningeal carcinomatosis; N/A, not applicable; ND, not done; NSCLC, non–small-cell lung cancer.
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among the most common sites of relapse in patients treated 
with crizotinib.3 Thus, it remains unclear whether develop-
ment of ISCMs and LC in these cases reflects true biologic 
progression or a pharmacokinetic failure in the CNS.
Several next-generation ALK inhibitors are currently in 
clinical development. In early phase studies, several of these 
agents have shown activity in patients with brain metastases, 
perhaps reflecting increased potency and/or improved CNS 
penetration.17–19 For example, in a recent phase I/II study of 
the next-generation ALK inhibitor CH5424802, three ALK-
positive patients were enrolled with untreated brain metasta-
ses.19 All three experienced responses in the brain after treatment 
with CH5424802, and two of three patients remained on ther-
apy for more than 300 days without progression. Nevertheless, 
there is currently a lack of data on the rate and durability of 
CNS responses in patients treated with next-generation ALK 
inhibitors. It also remains unclear whether responses in the 
brain will translate into activity within other compartments of 
the CNS, such as the leptomeninges or spinal cord. Altogether, 
this underscores the need for CNS-specific cohorts within clin-
ical trials of next-generation ALK inhibitors.
In summary, NSCLC patients with ALK rearrangements 
may present with metastatic involvement of sanctuary sites 
such as the brain, leptomeninges, and spinal cord. Clinicians 
should consider neuroimaging, including evaluation of the 
spine, in ALK-positive patients with neurologic symptoms. 
This report also highlights the need to develop novel ALK 
inhibitors with improved CNS penetration and antitumor 
activity.
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